everyone. morning, you, and Thank Mark, good
want I and listen sector, health to life to sciences safe to call. workers times. find to for unprecedented of commitment in well is serve First everywhere your hope as and and families this and Lantheus extraordinary proud their thank each you foremost, these care the we you
essential. Bob basis, deemed call. daily, to and of discuss included reduced the the will manufacture our been I Lantheus' products And in ship as we products and list products a have campus on during from continue although
The nuclear of proud the our microbubble the who the to production have of entire safety is we team, adopted products, of priority, the and times. as medicine or support our working ensure dedication receive measures and heightened employees manufacturing our products. a our they I very that ongoing facilities at these am is patients of are during of in Lantheus whether home challenging and
ahead of as global volumes we in while results quarter first announced were company April the X On that of COVID-XX business expectations, declined. our products months mid-March, X, the reached for procedural through first levels pandemic
that of would we business the quarter. the seen be second pandemic in on that the also anticipated We first more COVID-XX our quarter than significant noted impact
until that at levels procedures health products steps taken recover. already for ongoing reduce had care we of cost elective by impacted our Accordingly, demand within to time the systems reduction
reduced effective activities for with significant In increase our and spending, and of addition to work we second the the higher demand. of to better X reduction XX, days balance we from distribution a XXXX, to supply, balance have Further, in of XXXX. the implemented align days reduced quarter, week X manufacturing, other order discretionary product April through
our the for other hourly our of our for XX% and for including reduced for a XX% hours executive our for across for period. of same for also reduction President a employees Board and pay members a personnel, XX% Vice of team, employees that reduction We our XX% reduction reduction of myself, salaried XX% salaries
on has stock of for anniversary elected payable in of the form rather year In restricted compensation will remaining of in and the the second all addition, of also receive our XXXX member cash. Directors vest and Board than the time-based director to has compensation the XX% first in committee half reduced granting units by that
confident these meet start to needs elective we customers' our return procedures despite across as We poised that to are measures, are the country.
company to continuity business precautionary supply also manufacturing in our and facilities. management, strategically in measures ensure chain capabilities The an implemented effort other
employees Protective been always protected Our with and have nuclear manufacturer are Equipment, manufacturing a we PPE, sterile or Personal appropriate products. of as
adopted to our have We additional and ensure suites. appropriate measures distancing social safety manufacturing measures in increased
another level, the in trends demonstrating the pandemic. our continue of At I'll healthy we DEFINITY the to business begin year impact franchise, DEFINITY. and for the to prior our our patent product delivered to portfolio. were strong XXXX start with microbubble portfolios bolster
covering were our recently Book. method-of-use Orange the of in issued DEFINITY three month, listed this patents Earlier
the of expires X XXXX. patents in expire them One of at and these end XXXX, of
patents DEFINITY patent listed in Our total. includes - patent Orange X Book portfolio now
of Also, eligible for call Orange DEFINITY RT. also as Once for would hold of second-generation patent listing matter at we composition that end matter by approved that disclosed we be of the FDA, of the our patent formulation we previously, expires have product in DEFINITY, composition Book. modified XXXX which the the is that
We patents DEFINITY prepared relating DEFINITY portfolio vigorously our we infringers. worldwide, and defend to continue against are and to patent potential prosecute to RT
Regarding notice growth of we future. the ANDA not property intellectual our status We have for of a an DEFINITY to received application. our prospects potential in generic and filer, to send plan remain date, confident the
license XX, in development On import Medical March of use National the to partner, we important an for the DEFINITY with with the quarter Chinese DEFINITY development for echocardiography Double-Crane the our pharmaceutical NMPA, was application drug Product filed or company. Administration, indication. Another relating
kidney indications. the results work also license our import DEFINITY Double-Crane application those efforts liver of relating to This drug also important process and in is China. is us prepare in an will with the in and the milestone to an to indications commercialize analyzing clinical
LVEF results, for we of Benefit to unenhanced measurement ejection of echocardiography contrast-enhanced noncontrast there concluded X no announced results the DEFINITY BENEFIT improvement the contrast-enhanced accuracy III echocardiography multi-center our LVEF, of reproducibility ventricular where unenhanced to we study the versus used and February, X, first CMRI, CMRI. statistically or X and In as accuracy standard. left studies was cardiac fraction, reviewing truth imaging, or After significant resonance as echocardiography a Phase open-label were evaluate magnetic compared values of the in
In addition, improvement contrast-enhanced assessments. no analyses between and inter-reader LVEF in of unenhanced secondary the variability endpoints echocardiograms revealed for the
had review those results. X, study, opportunity the results are second that the similar now to X Namely results X also Benefit Phase to primary have III previously We Benefit its the our study study meet and of the endpoint. Benefit did not reported
volume of secondary measurements inter-reader the left endpoints versus when Among variability ultrasound. improved Benefit unenhanced for DEFINITY using ventricular X,
with LVEF echocardiography CMRI. when statistically left volume in significant no versus compared the While did there show inter-reader post-hoc ventricular was contrast-enhanced analysis unenhanced variability. to both improvements and improvement systolic measurements a in studies, In diastolic
the for of very we the At suboptimal the indication or effort border. opacify the of LVEF additional ventricular point, endocardial in Although chamber do continued left delineation echocardiograms time see an to ventricular much we not spending pursuing value contrast use DEFINITY. left this and improve foresee the of
Now our balance we'd update XXXX. an like what to moly provide expect the for for supply the on and first of we quarter
ANSTO as ANSTO Safety to supply. utilize will With the Lantheus to can Radiation a And first be it Agency, its ARPANSA, international has to late priority XXXX. their approved to been that you approval, Protection this customers. approval produce Nuclear the March ANSTO resume regulatory satisfy this customer, capacity. levels receive at supply In announced Australian to from and domestic year, of additional received If recall, late demand since that
evolved, of a transportation has supply for As dynamic the COVID-XX international availability situation. pandemic logistics has inbound the been
we uncertainties we and in While able U.S. been to challenges, for the flights, our serve. secure have products we markets meet other have to experienced being demand able nuclear
our to Progenics now pending Turning acquisition.
amended As June volatility XX, you know, announced XX, that in More pandemic. XXXX, to the restated announced into level we respective the agreement. that from April with meetings given an we special high we Progenics Board February, recently, and COVID-XX the entered caused had capital rescheduled by jointly markets XXXX, in of our merger we
we our Progenics, April merger obligations favor be proposed agreement Meeting a addition, and the XX, entered Lantheus in and affiliates in Annual Velan they set agreement. bound Lantheus vote forth which Progenics, has by into through In approving agreed with support on to to between that of standstill XXXX of certain announced that the together as and certain Capital to with
our in remain compelling combining I efforts. of by be I'm two value Since encouraged planning by could that and October, our first unlocked changed. combining our not has business, the the merger about very announcing the integration the of companies convinced rationale strategic progress
National proud XX,XXX to share products, sterile life that state am as of pieces to gowns our the home of went responders science and I first donate masks, Guard company manufacturing PPE to by Massachusetts. a were collected including able gloves. These in PPE, we
so for responders able We service contribution. and to everywhere, make a such first privileged be of we're grateful brave are to the
Bob. to turn that, Bob? I'll over With the call
